Our multi-modality team player.
CiĢýCa therapy
Think CiĢýCa therapy.
Your responsibility in good hands.
Your professional world is changing constantly. You appreciate technologies that are continuously evolving and help you to provide your patients with even better therapy. We would like to support you by offering a comprehensive approach for citrate anticoagulation-based CKRT: CiĢýCa therapy.
At a time when healthcare professionals are increasingly involved in non-caregiving activities such as administration, treatment documentation and medication preparation, there is a growing need for reliable, one-stop solutions which decrease the strain on the ICU staff.
Ģý is the first provider to offer a complete range of CiĢýCa therapy products from a single source, supporting healthcare professionals to focus on the essential: patient care.
Regional citrate anticoagulation enables patient treatment with less bleeding complications and less filter clotting compared to heparin CKRT.1Ģý3As one option to implement regional citrate anticoagulation, CiĢýCa therapy is an effective and reliable alternative to heparin4Ģý11and lets your ICU staff focus more on the patient and less on handling issues.5,11
Participate in our experience: Ģý was the first to offer a completely machine integrated CiĢýCa regional citrate anticoagulation. Healthcare professionals in more than 30 countries have already gained experience with CiĢýCa therapy and appreciate its reliable and easy application in clinical routines.5,6
Our proven citrate protocol is integrated in themultiFiltratePROand reflected in all our CiĢýCa products.
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">Automatisierte Peritonealdialyse (APD)</span></h3>
- <h3><span class="text-deep-blue">In-center HD</span></h3>
Think reliable.
Think CiĢýCa therapy.
Your question
What is the advantage of CiĢýCa therapy over standard heparin treatment?
Our answer
Citrate anticoagulation-based CKRT enables excellent patient treatment with fewer bleeding complications and less filter clotting compared to heparin.1,3,12,13CiĢýCa regional anticoagulation is an effective and reliable alternative to heparin:
- Proven citrate protocol5Ģý8
- Enabling adherence to KDIGO AKI guideline2
- Low associated bleeding risk5,7,8
- Long filter patency4,6,8,10
Think smart.
Think CiĢýCa therapy.
Your question
How can CiĢýCa therapy give me moreplannability and reduce my workload?
Our answer
Compared to heparin anticoagulation, CiĢýCa therapy reduces the number of nurse interventions, and facilitates efficient work planning:
- Prolonged filter lifetime corresponds to fewer filter changes4,10
- Low bleeding risk with expectedly fewer interventions needed5,7,8
- CiĢýCa Therapy protocol and products support a predictable workflow5,11
Think valueĢýbased.
Think CiĢýCa therapy.
Your question
How does CiĢýCa therapy support a valueĢýbasedapproach and help to meet budget requirements?
Our answer
CiĢýCa therapy may improve your CKRT cost structure and total cost of ownership compared to systemic anticoagulation:5,14
- Fewer bleeding events, potentially resulting in a lower number of required blood transfusions5,15
- Less filter clotting leads to fewer treatment interruptions, reducing the workload and increasing the plannability of tasks4,5,10,11
- The smart CiĢýCa protocol enables efficient consumption of fluids by avoiding relevant predilution16,17
Think partner.
Think CiĢýCa therapy.
Your question
WhatĢýs the benefit for our hospitalwhen switching to CiĢýCa therapy?
Our answer
Ģý can be your trusted one-stop business partner:
- With our comprehensive CiĢýCa therapy portfolio of tailored products and services, we offer what you need for a reliable and effective CKRT4Ģý11from a single source.
- As the world's leading provider of products and services for individuals with kidney diseases, we are able to provide the full range of support required for switching to CiĢýCa therapy as well as for daily operation.
Related content
1Tsujimoto H et al. Cochrane Database Syst Rev. 2020; 12(12):CD012467
2KDIGO Clinical Practice Guideline for Acute Kidney Injury., Kidney Int Suppl 2012; 2:1Ģý138
3Bai M et al. Intensive Care Med 2015; 41:2098Ģý2110
4Bianchi NA et al. Blood Purif 2020; 49:567Ģý575
5Kalb R et al. Ther Apher Dial 2013; 17:202Ģý212
6Morgera et al. Crit Care Med 2009;37:2018Ģý2024
7Slowinski T et al. Crit Care 2015; 19:349
8Link A et al. Crit Care 2012; 16:R97
9Huguet M et al. Int J Artif Organs 2017; 40:676Ģý682
10Hafner S et al. J Intensive Care 2015; 3:35
11Houllé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35Ģý41
12Hetzel GR et al. Nephrol Dial Transpl 2011; 26:232Ģý239
13Zarbock A et al. JAMA 2020; 324:1629Ģý1639
14Dalhuisen A et al. Neth J Crit Care 2017; 25:122Ģý127
15Kindgen-Milles D et al. Curr Opin Crit Care 2018; 24:450Ģý454
16Huang Z et al. Int J Artif Organs 2008, 31:525Ģý534
17Nalesso F et al. J Clin Med 2020; 9:1529